EYE
Nova EYE Medical Limited
๐ฆ๐บ ASX
๐ฉบ HEALTH CARE
๐ Overview
๐ Performance
๐ฐ Dividends
๐ต Cost
๐ค Advanced
๐จโ๐ฉโ๐งโ๐ฆ Community
๐
-13.19%
Annual Growth
5 years average annual growth
๐ฐ
34.62%
Annual dividend yield
Based on the most recent dividend
๐ต
$ 500
Minimum Order
Due to regulatory requirements
๐
4
Pearlers Invested
Since January 2020
๐ Overview
Key information
๐ Fund Overview
Nova Eye Medical Ltd. engages in developing suite of novel ophthalmic treatment technologies. The company is headquartered in Adelaide, South Australia. The firm operates through three segments: AlphaRET, and Glaucoma surgical devices. The Companyโs AlphaRET segment is responsible for the commercialization of the 2RT ophthalmic laser, which is an ophthalmic laser developed for the therapy of patients in the early to intermediate stages of age-related macular degeneration (AMD). 2RT is a patented nano-pulse laser device that rejuvenates retinal structures compromised by AMD. The Glaucoma Surgical Devices segment includes the designing, manufacturing, marketing, and sale of the iTrack, iTrack Advance and the Molteno3 glaucoma surgical device. The Molteno3 glaucoma drainage device platform is designed to enhance surgical utility and optimize clinical outcomes for long-term intraocular pressure (IOP) control in cases of severe glaucoma.
๐ Performance
Price History
-25.58%
1M
1Y
10Y
Graph
Table
Unsure how much or often to invest?
๐๏ธ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out โ๐ต Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out โโฑ๏ธ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out โ๐ฐ Dividends
Payouts
๐ฐ Annual Dividend Yield*
34.62%
๐ฐ Annual Dividend Earnings Per $1,000 invested**
$346.15
๐ฐ Most Recent Dividend Franked Percentage Estimate
100.00%
๐ฐ Average Dividend Franked Percentage Estimate
100.00 %
๐ฐ Dividend reinvestment
* Based on the most recent dividend
** Calculated by multiplying the most recent dividend yield by $1,000
Estimate your dividend
If you held
$
of EYE, your last dividend payment(s) would have been:
$ 2,488.48
on Wed Jul 29 2020
*Disclaimer: The information provided in this calculator is only a model to show you how long you need to invest for to achieve your goal, based on several factors, including past performance which is not an indicator of future performance. It is not a prediction and relies on assumptions, such as interest rates, that may vary and change the actual outcome. The results shown are only estimates and are not intended to be relied on when making a financial decision. Consider whether to get advice from a licensed financial adviser before making any financial decision.
Dividend History
1Y
5Y
10Y
Graph
Table
Year
Yearly Dividend Earnings Per Share
Franking Estimate
2025
$0.00
0.00%
2024
$0.00
0.00%
2023
$0.00
0.00%
2022
$0.00
0.00%
2021
$0.00
0.00%
2020
$0.14
100.00%
2019
$0.00
0.00%
2018
$0.00
0.00%
2017
$0.00
0.00%
2016
$0.00
0.00%
๐ต Costs
๐ผ
N/A
Management Fee
Included in unit price, not charged by Pearler
๐ธ
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
๐ธ Net fee calculator๐ค Advanced information
Technical Info
๐ฐ Price*
$0.13
*Price may be up to 24 hours old
๐ฉโ๐ฉโ๐ฆ Community Insights
How our community is investing
๐ Pearlers invested in EYE
4
๐ Total Capital Earnings
$-21.34
๐ Average investment frequency
15 weeks
๐ต Average investment amount
$5,221
โฐ Last time a customer invested in EYE
83 days
EYE investor breakdown
๐ต Income of investors
More than 200k
150k - 200k
100k - 150k
40%
50k - 100k
40%
Less than 50k
๐ถ Age of investors
18 - 25
50%
26 - 34
35 - 90
50%
๐ Legal gender of investors
Female
Male
100%
Pearlers who invest in EYE also invest in...
VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.
๐ Performance (5Yr p.a)
3.17%
๐ Share price
$102.68 AUD
๐งฑ MATERIALS
โณ๏ธ DIVERSIFIED
๐ธ FINANCIALS
๐ฆ๐บ AUSTRALIA
PYC Therapeutics Ltd is a AU-based company operating in Biotechnology industry. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2005-03-30. PYC Therapeutics Limited is an Australia-based clinical-stage biotechnology company creating a new generation of ribonucleic acid (RNA) therapies to change the lives of patients with genetic diseases. The firm utilizes its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. Its drug development programs target monogenic diseases - the indications with the highest likelihood of success in clinical development. Its first-in-class drug programs include Retinitis Pigmentosa type 11, (VP-001), Polycystic Kidney Disease, (PYC-003), Autosomal Dominant Optic Atrophy (ADOA) (PYC-001) and Phelan-McDermid Syndrome (PMS) (PYC-002). The firm's VP-001 program is a lead asset for a blinding eye disease of childhood progressed through multiple patient cohorts in the ongoing single ascending dose clinical trial. ADOA is a progressive and blinding eye disease.
๐ Performance (5Yr p.a)
378.18%
๐ Share price
$1.25 AUD
๐งฌ BIOTECHNOLOGY
Bellevue Gold Ltd. engages in the exploration and evaluation of minerals and mine development in Australia. The company is headquartered in Perth, Western Australia. The company went IPO on 2005-12-20. The Bellevue Gold Project is located in the northern part of the Norseman Wiluna Greenstone belt in the Yilgarn Craton, Western Australia. The project is approximately 40 kilometers (km) north (by sealed highway) from the regional center of Leinster and covers approximately 1,930 square kilometers (km2) of mining and exploration licenses. The project represents one of Australia's highest-grade gold mines, with a Mineral Resource of approximately 3.1 million ounces (Moz) at 9.9 grams per ton (g/t) global grade resource.
๐ Performance (5Yr p.a)
17.03%
๐ Share price
$1.19 AUD
โ๏ธ MINING
๐ HIGH PRICE GROWTH
Arafura Rare Earths Ltd. engages in the exploration and development of mineral resource properties. The company is headquartered in Perth, Western Australia. The company went IPO on 2003-11-05. The firm produces rare earth products from the Nolans Project. The Nolans Project consists of a mine, process plant, including beneficiation, extraction and separation plants, and related infrastructure to be constructed and located at the Nolans site, approximately 135 kilometers north of Alice Springs in Australia's Northern Territory. Its rare earth products are Neodymium-Praseodymium (NdPr) oxide, and Mixed middle-heavy rare earths (SEG/HRE) oxide. NdPr oxide is the Company's flagship product, which is used by magnet and magnet alloy customers. The Companyโs primary products from the Nolans project are rare earths, which are used in catalytic converters in automobiles, consumer electronics, energy efficiency lighting, optics, alloys, advanced ceramics and permanent magnets that enable e-mobility and renewable energy applications.
๐ Performance (5Yr p.a)
20.28%
๐ Share price
$0.14 AUD
๐ HIGH PRICE GROWTH
โ๏ธ MINING
NDQ.AX was created on 2015-05-26 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The fund aims to track the performance of the NASDAQ-100 Index (before fees and expenses). The NASDAQ-100 comprises 100 of the largest non-financial companies listed on the NASDAQ market, and includes many companies that are at the forefront of the new economy.
๐ Performance (5Yr p.a)
23.00%
๐ Share price
$51.24 AUD
๐ HIGH PRICE GROWTH
๐ค TECHNOLOGY
๐บ๐ธ UNITED STATES
Want more shares? Try these...